Kepler Capital analyst Justine Telliez maintained a Buy rating on Abivax SA on October 6 and set a price target of €70.00. The company’s shares closed yesterday at €73.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Telliez is a 5-star analyst with an average return of 62.9% and a 54.72% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Abivax SA, and Adocia SA.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abivax SA with a €85.00 average price target.
0RA9 market cap is currently €5.93B and has a P/E ratio of -27.22.
Read More on GB:0RA9:
Disclaimer & DisclosureReport an Issue
- Abivax price target raised to $120 from $112 at BTIG
- Abivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy Rating
- Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint
- Promising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s Obefazimod
- Abivax price target raised to $114 from $95 at Citizens JMP
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
